Last updated: February 24, 2026
What is the Scope of DK1893612?
DK1893612 is a pharmaceutical patent filed in Denmark. It claims protection for a specific formulation, method, or compound involving a therapeutic agent. The scope primarily covers:
- Chemical composition: Details specific active ingredients and their combinations.
- Method of use: Claims methods for treating or preventing certain diseases.
- Formulation specifics: Describes formulation parameters such as dosage forms, excipients, or delivery mechanisms.
The scope depends on the language of the claims, which are crafted to encompass the novelty of the invention while avoiding prior art. The patent's claims define the legal boundaries and include independent claims covering the core invention and dependent claims adding specific embodiments.
What are the Key Claims of DK1893612?
An analysis of the claims indicates that:
-
Independent Claims: Usually describe a novel chemical entity or its use. For example, claim 1 might define a compound with a specific structure or a method of treatment involving the compound.
-
Dependent Claims: Narrow application, specify particular dosages, formulations, or methods, such as administration routes or combinations with other agents.
Sample Claim Structure (hypothetical):
- A pharmaceutical composition comprising [active compound] having the structure of [specific structure].
- The composition of claim 1, wherein the active compound is administered via oral route.
- The composition of claim 1, further comprising a pharmaceutically acceptable excipient.
Claim Language and Scope
The language employs standard patent claiming methods—broad claims followed by narrower claims. The most robust protection is usually from the independent claim, which covers the core invention. Claims are crafted to balance broad protection with the risk of invalidation by prior art.
Patent Landscape for Similar and Related Patents
Geographical Coverage
While DK1893612 is Danish, similar patents often exist in the European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and internationally via the Patent Cooperation Treaty (PCT).
- European Patent Landscape: Multiple patents filed for similar compounds or formulations in Europe, often overlapping in scope.
- US Patent Landscape: A substantial number of patents cover the same therapeutic class or chemical structures.
- International Patents: Broad filings by major pharmaceutical companies targeting global markets.
Patent Classes and Keywords
- Patent searches utilize relevant International Patent Classification (IPC) codes, such as C07D (Heterocyclic compounds), A61K (Medical preparations), etc.
- Key search terms involve the active compound's chemical name, therapeutic target, and formulation types.
Major Patent Assignees and Filers
- Research-based pharma: Companies like Novartis, Pfizer, and AstraZeneca often hold patents in similar areas.
- Biotech companies: Focused on novel compounds or delivery systems.
- Academic institutions: Contribute to early-stage patents, often citing initial research.
Legal Events and Patent Status
- Monitor grants, oppositions, and examinations. The DK1893612 patent may have been granted, opposed, or still under examination.
- The scope could be challenged if prior art suggests obviousness or novelty issues.
Patent Term and Expiry Dates
- Patent term likely 20 years from filing, with possible extensions for testing or regulatory delays.
- Check official patent register for exact expiration date and status.
Legal and Commercial Implications
- The patent potentially blocks generics within Denmark and can serve as a basis for extension through supplementary protection certificates (SPC) in Europe.
- It influences licensing negotiations, production strategies, and competitive positioning.
Key Takeaways
- The scope of DK1893612 focuses on a specific chemical composition or method of use, with protection defined by its claims.
- The claims range from broad (covering the compound or method) to narrow (specific formulations or administration routes).
- The patent landscape is crowded in related therapeutic areas, with overlapping patents and similar claims filed internationally.
- Patent validity and enforceability depend on prior art, claim language, and legal proceedings.
- Market exclusivity relies on maintaining patent rights through timely legal strategies and potential extensions.
5 FAQs
1. How broad are the claims typically in DK1893612?
The broadness depends on the independent claims; they generally aim to encompass the core compound or method with narrower dependent claims protecting specific embodiments.
2. Are there similar patents in Europe or the US?
Yes, similar patents are filed across jurisdictions, often in the same therapeutic class or involving the same chemical structures.
3. What is the active ingredient involved in DK1893612?
The specific active ingredient details are in the patent document; typically, this involves a novel chemical entity or its therapeutic use.
4. How does patent term extension affect DK1893612?
In Denmark and Europe, extensions can provide additional protection beyond the initial 20 years if regulatory approval delays.
5. What are common challenges to patent validity for such drugs?
Prior art, obviousness, and lack of novelty are frequent grounds for challenge.
Sources
[1] European Patent Office. (2022). Patent information. Retrieved from https://www.epo.org/patents/using.html
[2] World Intellectual Property Organization. (2022). Patent landscape reports. https://www.wipo.int/landscape/en/
[3] Danish Patent Office. (2022). Patent database. https://danishpatent.dk/
Note: Specific claims content and legal status of DK1893612 require access to official patent documents.
